BACKGROUND: AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological (NP) effects of 3 antiretroviral regimens in participants infected with human immunodeficiency virus type 1 (HIV-1) in resource-limited settings. METHODS:Participants from Brazil, India, Malawi, Peru, South Africa, Thailand, and Zimbabwe were randomized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) as part of the ACTG PEARLS study (A5175). Standardized neurological and neuropsychological (NP) screening examinations (grooved pegboard, timed gait, semantic verbal fluency, and finger tapping) were administered every 24 weeks from February 2006 to May 2010. Associations with neurological and neuropsychological function were estimated from linear and logistic regression models using generalized estimating equations. RESULTS: The median weeks on study was 168 (Q1 = 96, Q3 = 192) for the 860 participants. NP test scores improved (P < .05) with the exception of semantic verbal fluency. No differences in neurological and neuropsychological functioning between treatment regimens were detected (P > .10). Significant country effects were noted on all NP tests and neurological outcomes (P < .01). CONCLUSIONS: The study detected no significant differences in neuropsychological and neurological outcomes between randomized ART regimens. Significant improvement occurred in neurocognitive and neurological functioning over time after initiation of ARTs. The etiology of these improvements is likely multifactorial, reflecting reduced central nervous system HIV infection, better general health, and practice effects. This study suggests that treatment with either of the World Health Organization -recommended first-line antiretroviral regimens in resource-limited settings will improve neuropsychological functioning and reduce neurological dysfunction. CLINICAL TRIALS REGISTRATION: NCT00096824.
RCT Entities:
BACKGROUND:AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological (NP) effects of 3 antiretroviral regimens in participants infected with human immunodeficiency virus type 1 (HIV-1) in resource-limited settings. METHODS:Participants from Brazil, India, Malawi, Peru, South Africa, Thailand, and Zimbabwe were randomized to 3 antiretroviral treatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) as part of the ACTG PEARLS study (A5175). Standardized neurological and neuropsychological (NP) screening examinations (grooved pegboard, timed gait, semantic verbal fluency, and finger tapping) were administered every 24 weeks from February 2006 to May 2010. Associations with neurological and neuropsychological function were estimated from linear and logistic regression models using generalized estimating equations. RESULTS: The median weeks on study was 168 (Q1 = 96, Q3 = 192) for the 860 participants. NP test scores improved (P < .05) with the exception of semantic verbal fluency. No differences in neurological and neuropsychological functioning between treatment regimens were detected (P > .10). Significant country effects were noted on all NP tests and neurological outcomes (P < .01). CONCLUSIONS: The study detected no significant differences in neuropsychological and neurological outcomes between randomized ART regimens. Significant improvement occurred in neurocognitive and neurological functioning over time after initiation of ARTs. The etiology of these improvements is likely multifactorial, reflecting reduced central nervous system HIV infection, better general health, and practice effects. This study suggests that treatment with either of the World Health Organization -recommended first-line antiretroviral regimens in resource-limited settings will improve neuropsychological functioning and reduce neurological dysfunction. CLINICAL TRIALS REGISTRATION: NCT00096824.
Authors: Kevin R Robertson; Wendy T Robertson; Sutapa Ford; David Watson; Susan Fiscus; Amanda G Harp; Colin D Hall Journal: J Acquir Immune Defic Syndr Date: 2004-05-01 Impact factor: 3.731
Authors: Kevin Robertson; Johnstone Kumwenda; Khuanchai Supparatpinyo; Jeanne H Jiang; Scott Evans; Thomas B Campbell; Richard W Price; Robert Murphy; Colin Hall; Christina M Marra; Cheryl Marcus; Baiba Berzins; Reena Masih; Breno Santos; Marcus T Silva; N Kumarasamy; Ann Walawander; Apsara Nair; Srikanth Tripathy; Cecilia Kanyama; Mina Hosseinipour; Silvia Montano; Alberto La Rosa; Farida Amod; Ian Sanne; Cindy Firnhaber; James Hakim; Pim Brouwers Journal: J Neurovirol Date: 2011-07-23 Impact factor: 2.643
Authors: Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein Journal: J Neurovirol Date: 2002-04 Impact factor: 2.643
Authors: J J Sidtis; C Gatsonis; R W Price; E J Singer; A C Collier; D D Richman; M S Hirsch; F W Schaerf; M A Fischl; K Kieburtz Journal: Ann Neurol Date: 1993-04 Impact factor: 10.422
Authors: Kevin R Robertson; Hongyu Jiang; Johnstone Kumwenda; Khuanchai Supparatpinyo; Christina M Marra; Baiba Berzins; James Hakim; Ned Sacktor; Thomas B Campbell; Jeffrey Schouten; Katie Mollan; Srikanth Tripathy; Nagalingeswaran Kumarasamy; Alberto La Rosa; Breno Santos; Marcus T Silva; Cecilia Kanyama; Cindy Firhnhaber; Robert Murphy; Colin Hall; Cheryl Marcus; Linda Naini; Reena Masih; Mina C Hosseinipour; Rosie Mngqibisa; Sharlaa Badal-Faesen; Sarah Yosief; Alyssa Vecchio; Apsara Nair Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 9.079
Authors: Kristine M Erlandson; Jennifer A Schrack; Catherine M Jankowski; Todd T Brown; Thomas B Campbell Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: K Robertson; H Jiang; S R Evans; C M Marra; B Berzins; J Hakim; N Sacktor; M Tulius Silva; T B Campbell; A Nair; J Schouten; J Kumwenda; K Supparatpinyo; S Tripathy; N Kumarasamy; A la Rosa; S Montano; A Mwafongo; C Firnhaber; I Sanne; L Naini; F Amod; A Walawander Journal: J Neurovirol Date: 2016-01-05 Impact factor: 2.643